Live Breaking News & Updates on Allergan Ozurdex

Stay updated with breaking news from Allergan ozurdex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029 - Press Release


Global Diabetic Retinopathy Drug Forecast and Market Analysis to 2029
ResearchAndMarkets.com s offering.
Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF).
The most frequently used anti-VEGF drugs are Roche/Genentech s humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regeneron s fusion protein Eylea (aflibercept). Angiotensin converting enzyme (ACE) inhibitors can be used to treat patients with comorbid hypertension and diabetic retinopathy, while corticosteroids Alimera s Iluvien (fluocinolone acetonide), Allergan s Ozurdex (dexamethasone), and MaQaid (triamcinolone acetonide) can be used to treat people with RVO. ....

United Kingdom , Roche Genentech , Roche Lucentis , Bayer Regeneron Eylea , Allergan Ozurdex , Alimera Iluvien , Kanghong Pharma , Laura Wood , Bayer Regeneron , Custom Research , Office Hours Call , Boehringer Ingelheim , E St Office Hours Call , Drug Forecast , Market Analysis , Graybug Vision , Chengdu Kanghong , Senior Press Manager , Free Call , Hours Call , ஒன்றுபட்டது கிஂக்டம் , ரோச் ஜெநிஂடெக் , லாரா மரம் , தனிப்பயன் ஆராய்ச்சி , அலுவலகம் மணி அழைப்பு , போஹெரிங்கர் இஂகல்‌ஹைம் ,